American Heart Association Scientific Sessions 2017

American Heart Association Scientific Sessions 2017
The American Heart Association Scientific Sessions 2017 brings together nearly 18,000 attendees from 100 countries to present the latest cutting-edge science and clinical practices in cardiovascular science and medicine. The Sessions will be held November 11-15, 2017, in Anaheim, California. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
December 17, 2017
A new pathway uses a multidisciplinary team to help reduce 30-day heart failure readmissions, explained Amar Bhakta, MD, of Rush University Medical Center.
November 26, 2017
As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
November 16, 2017
The new hypertension guidelines made major changes to the classification of blood pressure, in general, and changed the name of one category to convey more importance, explained Robert Carey, MD, MACP, professor of medicine and dean emeritus at the University of Virginia.
November 16, 2017
New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
November 15, 2017
Reimbursement policy has been a driver of change in the way hospitals handle heart failure patients.
November 15, 2017
The findings, presented at the 2017 American Heart Association Scientific Sessions, suggest that a "precision medicine" approach to tailoring adherence strategies to individual patients may be needed, according to the study's lead author.
November 15, 2017
Recent results from a team-based, scalable intervention to promote medication adherence highlighted that the relationship between adherence and clinical outcomes is not always clear cut, said Niteesh Choudhry, MD, PhD, associate professor at Harvard Medical School.
November 15, 2017
The outcomes in the COMPASS trial of rivaroxaban to treat patients with peripheral artery disease have been very positive, and a new analysis has looked at the cost impact of bringing the drug to market, explained Andre Lamy, MD, MHSc, FRSC, a cardiac surgeon with the Population Health Research Institute in Hamilton, Ontario, Canada.
November 15, 2017
The analysis presented at the American Heart Association looks strictly at healthcare costs, but a broader cost-effectiveness study is planned that will consider drug costs as well as effect on patient quality of life.
November 14, 2017
Researchers presenting at the American Heart Association look at specific populations within 2 large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome to the new and improved, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!